WS
GYRE icon

Wedbush Securities’s Gyre Therapeutics GYRE Stock Holding History

Wedbush Securities’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-3,064
Closed -$99K – 921
2020
Q3 		$99K Buy
+3,064
New +$120K 0.01% 831
2019
Q4 		– Sell
-2,709
Closed -$100K – 1006
2019
Q3 		$100K Buy
+2,709
New +$146K 0.01% 898
2017
Q1 		– Sell
-329
Closed -$24K – 862
2016
Q4 		$24K Buy
329
+142
+76% +$12.8K ﹤0.01% 800
2016
Q3 		$25K Buy
187
+67
+56% +$10.1K ﹤0.01% 812
2016
Q2 		$20K Buy
+120
New +$20.5K ﹤0.01% 763

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Wedbush Securities's GYRE Position: Q4 2020 in Review

Wedbush Securities sold out of Gyre Therapeutics (GYRE) in Q4 2020, closing a stake of 3,064 shares — an estimated $99K sold.

Wedbush Securities first reported a position in GYRE in Q2 2016 and held it in 5 quarters. The position peaked at $100K in Q3 2019. 80 funds tracked by Wall St. Rank hold GYRE as of Q4 2020.

  • Wedbush Securities reported no remaining Gyre Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Wedbush Securities sold 3,064 Gyre Therapeutics shares in Q4 2020, an estimated $99K.
  • Wedbush Securities first reported a position in Gyre Therapeutics in Q2 2016 and held it in 5 quarters.
  • Wedbush Securities's Gyre Therapeutics position peaked at $100K in Q3 2019.
  • 80 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2020.

Based on Wedbush Securities's 13F filing for Q4 2020, filed 16 Feb 2021.